Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Keytruda Filed for Tumor-Agnostic Indication in Japan
April 2, 2018
- Generic Use Rate at 68.9% in October-December: JGA
April 2, 2018
- Bayer Gives Update on Initiatives after Xarelto Survey Scandal
March 30, 2018
- Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
March 30, 2018
- Fujifilm to Gobble Up 2 Cell Culture Media Firms for US$800 million
March 30, 2018
- Takeda Gets Japan Rights to Ammonul from Valeant
March 29, 2018
- Tokyo Court Strikes Down Baxalta Claim against Hemlibra: Chugai
March 29, 2018
- Janssen Files Japan NDA for Apalutamide in CRPC
March 29, 2018
- Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
March 29, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
- Sumitomo Dainippon to Transfer Back Office Staffers to Dedicated Subsidiary
March 28, 2018
- Tokyo Upstart Curadim In-Licenses Drug Candidate for IPF/NASH
March 28, 2018
- Sumitomo Dainippon, Carna Bio Cut Deal on Kinase Inhibitor Research in Psychiatry/Neurology
March 28, 2018
- Enfortumab Vedotin Gets FDA Breakthrough Status in Urothelial Cancer: Astellas/Seattle Genetics
March 28, 2018
- Zeria Obtains Japan Rights to Veltassa from Vifor Pharma
March 28, 2018
- Mitsubishi Tanabe Explores Creation of Drug Safety Info. Database with Drug Makers: President
March 28, 2018
- Daiichi Sankyo to Launch Open Innovation Research on Novel Cancer Hyperthermia Therapy with Academia, Venture Capital
March 28, 2018
- Opdivo Gains Label Expansion in South Korea: Ono
March 27, 2018
- Shionogi, Kyoto Univ. Ink Research Collaboration for Psychiatric Disorders
March 27, 2018
- Asahi Kasei in Licensing Pact with RaQualia to Begin Preclinical Development for Novel Neuropathic Pain Candidate
March 27, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…